HRP20040411A2 - Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors - Google Patents
Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors Download PDFInfo
- Publication number
- HRP20040411A2 HRP20040411A2 HR20040411A HRP20040411A HRP20040411A2 HR P20040411 A2 HRP20040411 A2 HR P20040411A2 HR 20040411 A HR20040411 A HR 20040411A HR P20040411 A HRP20040411 A HR P20040411A HR P20040411 A2 HRP20040411 A2 HR P20040411A2
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- tautomer
- oxide
- methyl
- Prior art date
Links
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title claims description 14
- 108091008605 VEGF receptors Proteins 0.000 title description 4
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 32
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 25
- -1 perfluoro Chemical group 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 13
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 11
- 206010038923 Retinopathy Diseases 0.000 claims abstract description 10
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 8
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 112
- 239000000203 mixture Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 10
- 239000007858 starting material Substances 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- FFAYGOGQMRPYBF-UHFFFAOYSA-N 2-[(6-methoxypyridin-3-yl)methylamino]-n-[2-methyl-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=NC(OC)=CC=C1CNC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1C FFAYGOGQMRPYBF-UHFFFAOYSA-N 0.000 claims description 3
- MHEAGNMVORWXFF-UHFFFAOYSA-N 2-[(6-methoxypyridin-3-yl)methylamino]-n-[3-(trifluoromethyl)phenyl]benzamide;hydrochloride Chemical compound Cl.C1=NC(OC)=CC=C1CNC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 MHEAGNMVORWXFF-UHFFFAOYSA-N 0.000 claims description 3
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 32
- 206010064930 age-related macular degeneration Diseases 0.000 abstract description 8
- 241000282412 Homo Species 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000002253 acid Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 239000012071 phase Substances 0.000 description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 8
- 241000208199 Buxus sempervirens Species 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- OCASPBDTLFAPDS-UHFFFAOYSA-N 2-[(6-methoxypyridin-3-yl)methylamino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=NC(OC)=CC=C1CNC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 OCASPBDTLFAPDS-UHFFFAOYSA-N 0.000 description 3
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 201000008274 breast adenocarcinoma Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- POHRCZGMDBMSOM-UHFFFAOYSA-N 2-amino-n-[4-bromo-3-(trifluoromethyl)phenyl]benzamide Chemical compound NC1=CC=CC=C1C(=O)NC1=CC=C(Br)C(C(F)(F)F)=C1 POHRCZGMDBMSOM-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HOXWIPBKODBSID-UHFFFAOYSA-N n-[4-bromo-3-(trifluoromethyl)phenyl]-2-[(6-methoxypyridin-3-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC=C1CNC1=CC=CC=C1C(=O)NC1=CC=C(Br)C(C(F)(F)F)=C1 HOXWIPBKODBSID-UHFFFAOYSA-N 0.000 description 2
- UVSUTFBMELDTAY-UHFFFAOYSA-N n-[4-bromo-3-(trifluoromethyl)phenyl]-2-nitrobenzamide Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)NC1=CC=C(Br)C(C(F)(F)F)=C1 UVSUTFBMELDTAY-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- LELTXJWGZLSFGC-UHFFFAOYSA-N 2-[(6-methoxypyridin-3-yl)methylamino]-n-[4-prop-1-ynyl-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=NC(OC)=CC=C1CNC1=CC=CC=C1C(=O)NC1=CC=C(C#CC)C(C(F)(F)F)=C1 LELTXJWGZLSFGC-UHFFFAOYSA-N 0.000 description 1
- HRWKAQXJZCJELE-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridin-3-yl)methylamino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC2=CNC(=O)C=C2)=C1 HRWKAQXJZCJELE-UHFFFAOYSA-N 0.000 description 1
- SBDNDOXJCVRXJV-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridin-3-yl)methylamino]-n-[4-prop-1-ynyl-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C(F)(F)F)C(C#CC)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CNC(=O)C=C1 SBDNDOXJCVRXJV-UHFFFAOYSA-N 0.000 description 1
- TWLDBACVSHADLI-UHFFFAOYSA-N 2-methyl-3-(trifluoromethyl)aniline Chemical compound CC1=C(N)C=CC=C1C(F)(F)F TWLDBACVSHADLI-UHFFFAOYSA-N 0.000 description 1
- RBSRVSPQBYSSNA-UHFFFAOYSA-N 2-nitro-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 RBSRVSPQBYSSNA-UHFFFAOYSA-N 0.000 description 1
- BWWHTIHDQBHTHP-UHFFFAOYSA-N 2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1C(Cl)=O BWWHTIHDQBHTHP-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- YGNISOAUPSJDJE-UHFFFAOYSA-N 4-bromo-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(Br)C(C(F)(F)F)=C1 YGNISOAUPSJDJE-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010066453 Mesangioproliferative glomerulonephritis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- ZITKDVFRMRXIJQ-UHFFFAOYSA-N dodecane-1,2-diol Chemical compound CCCCCCCCCCC(O)CO ZITKDVFRMRXIJQ-UHFFFAOYSA-N 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- OTEDRGMTZQVECB-UHFFFAOYSA-N n-[2-methyl-3-(trifluoromethyl)phenyl]-2-[(6-oxo-1h-pyridin-3-yl)methylamino]benzamide Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC(=O)C1=CC=CC=C1NCC1=CNC(=O)C=C1 OTEDRGMTZQVECB-UHFFFAOYSA-N 0.000 description 1
- VQHLODSJYZKHPW-UHFFFAOYSA-N n-[2-methyl-3-(trifluoromethyl)phenyl]-2-nitrobenzamide Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC(=O)C1=CC=CC=C1[N+]([O-])=O VQHLODSJYZKHPW-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000013392 nude mouse xenograft model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- DBSMLQTUDJVICQ-CJODITQLSA-N onametostat Chemical compound NC1=C2C=CN([C@@H]3C[C@H](CCC4=CC=C5C=C(Br)C(N)=NC5=C4)[C@@H](O)[C@H]3O)C2=NC=N1 DBSMLQTUDJVICQ-CJODITQLSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108010005709 protein kinase C kinase Proteins 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000004341 tarsal joint Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- KCQJLTOSSVXOCC-UHFFFAOYSA-N tributyl(prop-1-ynyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C#CC KCQJLTOSSVXOCC-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 238000010518 undesired secondary reaction Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Izum se odnosi na nove derivate amida antranilične kiseline, postupke njihove proizvodnje, njihovu primjenu u postupku tretiranja ljudi i životinja, njihovu upotrebu- samih ili u kombinaciji s jednim ili više farmaceutskih spojeva- za tretiranje osobito neoplastičnih bolesti, kao što su tumorske bolesti, retinopatija i inakularne degeneracije povezane sa starosti; postupke za tretiranje takvih bolesti životinja, osobito u ljudi, i upotreba takvog spoja -samog ili u kombinaciji s jednim ili više drugih aktivnih spojeva - za proizvodnju farmaceutskih preparata (lijekova) za tretiranje neoplastičnih bolesti, retinopatija ili makularne degeneracije povezane sa starošću.
Poznato je da su određene bolesti povezane s dereguliranom angiogenezom, naprimjer bolestima uzrokovanim okularnom neoveskularizacijom, kao što su retinopatije (uključujući diabetičku retinopatiju), sa starosti povezanom makularnom degeneracijom, psorijazom, hemangioblastomom, hemangiomom, arteriosklerozom, upalnim bolestima, kao što su reurnatoidne ili reumatske upalne bolesti, posebno artritis, kao što je reumatoidni artritis, ili drugi kronični upalni poremećaji, kao što je kronična astma, arterijalna ili post-transplatacijska ateroskleroza, endometrioze, i osobito neoplastične bolesti, naprimjer takozvani čvrsti tumori i tekući tumori (kao što je leukemija).
U centru mreže regulacije rasta i diferencijacije vaskularnog vaskularnog sustava i njegove komponente tijekom razvoja embrija, normalan rast i veliki broj patoloških anomalija i bolesti, postojanje angiogenog faktora poznatih kao «vaskularni endotelialni faktor rasta» (VGEF), dimerični, disulfid-vezani 46-kDa glikoprotein, zajedno s njegovim celularnim receptorima (vidi Breier, G. , et al. , Trends in Cell Biology 6, 454-6 [1996]).
VEGF receptori su transmembrani receptori tirozin kinaze. Poznati su različiti tipovi VEGF receptora, npr. VEGPR-1, VEGFR-2 i VEGFR-3.
Veliki broj humanih tumora, osobito glioma i karcinoma, pokazuju visoki nivo VEGF i njihovih receptora. To dovodi do hipoteze da tako VEGF otpuštene tumorske stanice mogu stimulirati rast kapilara i proliferaciju tumorskog endotela na parakrini način i tako, preko osiguravanja dostave krvi, ubrzavajući rast. Direktno bilježenje uloge VEGF kao faktora angiogeneze tumora in vivo dobiveno je iz studija u kojima je VEGF aktivitet inhibiran protutijelima.
Angiogeneza se smatra apsolutno potrebnom za te tumore koji rastu preko maksimalnog dijametra od oko 1-2 mm; sve do tog limita, kisik i nutrijenti mogu biti dostavljeni difuzijom tumorskih stanica.
Tri glavna mehanizma igraju značajnu ulogu u aktivnosti inhibitora angiogeneze protiv tumora: 1) inhibicija rasta krvnih žila, osobito kapilara, u vaskularizaciji tumora, s rezultatom da to nije mrežasti rast tumora zbog balansa tako da je ispunjen između apoptoze i proliferacije; 2) prevencija migracije tumorskih stanica zbog odsutnosti protoka krvi u i iz tumora; i 3) inhibicija enditelijalne proliferacije stanica, tako dovodi do parakrinog rasta-stimulirajućeg učinka koji se očituje na okolnom tkivu s endotelijalnim stanicama s normalnim linijama krvnih žila.
U WO00/27820 su opisani spojevi koji pripadaju u klasu spojeva amida antranilične kiseline koji su navedeni da inhibiraju aktivnost VEGF receptor tirozin kinaze, rast tumora i VEGF-ovisne proliferacije stanica.
Neočekivano, je utvrđeno da derivati amida antranilične kiseline formule I, prikazane niže, ima poželjna farmakološka svojstva i inhibira, naprimjer aktivnost VEGF receptor tirozin kinaze, rast tumora i VEGF-ovisne proliferacije stanice.
Derivati amida antranilične kiseline formule I su prikladni, naprimjer, za upotrebu u tretiranju bolesti, osobito bolesti u tretiranju i isto za prevenciju onih, na koje pokazuju dobar učinak na inhibiciju angiogeneze i/ili VEGF receptor tirozin kinaze.
U izum spadaju amidi antranilične kiseline formule I,
[image]
gdje
R1 predstavlja H ili niži alkil,
R2 predstavlja H ili niži alkil,
R3 predstavlja perfluor niži alkil, i
X je O ili S
u njegovim N-oksidima i tautomerima,
i solima takvih amida antranilične kiseline, njegovim oksidima i tautomerima.
Opći pojmovi koji se koriste gore i dolje u tekstu preferirano unutar konteksta prikaza imaju sljedeće značenje, osim ako nije drugačije navedeno:
Prefiks «niži» označava da radikal ima sve do i uključujući maksimum 7, osobito sve do i uključujući maksimum 4 atoma ugljika, radikali u stvari su i linearni ili razgranati s jednim ili više granjanja.
Kada se koristi višestruki oblik za spojeve, soli, i slično, tada je uzeto značenje i za samo spoj, sol ili slično.
Bilo koji asimetrični atom ugljika (naprimjer u spojevima formule I, gdje R9 je niži alkil) može se predstaviti s (R)-, (S)- ili (R,S)-konfiguracijom, preferirano s (R)- ili (S)-konfiguracijom. Spojevi mogu tako biti prisutni kao smjesa izomera ili kao čisti izomeri, preferirano kao enantiomer-čisti diastereomeri.
Izum se odnosi i na moguće tautomere spojeva formule I. Pojam «tautomeri» korišten ovdje posebno se odnosi na spojeve formule I gdje R1 predstavlja H, a X je O ili S, koji spojevi isto postoje na istom nastavku, ako ne potpuno, u tautomernom obliku pokazanom dolje (I-tautomer), gdje drugi radikali i simboli imaju značenje definirano ovdje.
[image]
U preferiranom ostvarenju, alkil ima sve do maksimalno 12 atoma ugljika i osobito je niži alkil.
Niži alkil je preferirano alkil s od i uključujući 1 sve do i uključujući 7, preferirano od i uključujući l do i uključujući 4, i linearan ili razgranati, preferirani, niži alkil je butil, kao što je n-butil, sec-butil, izobutil, tert-butil, propil, kao što je n-propil ili izopropil, etil ili preferirano metil.
Pojam «perfluor niži alkil» koristi se ovdje u značenju niži alkil radikal gdje svi atomi vodika su zamijenjeni s atomima fluora.
Halogen je osobito fluor, klor, brom ili jod, osobito fluor, klor, ili brom.
Takve soli su formirane, naprimjer, kao soli dodanih kiselina, preferirano organskih ili anorganskih kiselina, od spojeva formule I s baznim atomom dušika, osobito farmaceutski prihvatljive soli. Prikladne anorganske soli su, naprimjer, halogene kiseline, kao što je klorovodična kiselina, sumporna kiselina, ili fosforna kiselina. Prikladne organske kiseline su, naprimjer, karboksilna kiselina, sulfonska ili sulfaminska kiselina, naprimjer octena kiselina, propionska kiselina, oktanoična kiselina, dekanoična kiselina, dodekanoična kiselina, glikolna kiselina, mliječna kiselina, fumarna kiselina, sukcininska kiselina, adipična kiselina, pimelična kiselina, azelaična kiselina, jabučna kiselina, vinska kiselina, liminska kiselina, amino kiseline kao što je glutaminska kiselina ili aspartinska kiselina, maleinska kiselina, hidroksimaleinska kiselina, metilnialeinska kiselina, cikloheksankarboksilna kiselina, adamantankarboksilna kiselina, benzojeva kiselina, salicilna kiselina, 4-aminosalicilna kiselina, ftalična kiselina, feniloctena kiselina, bademova kiselina, cinamična kiselina, metan- ili etan-sulfonska kiselina, 2-hidroksietansulfonska kiselina, etan-1,2-disulfonska kiselina, 2-naftalensulfonska kiselina, 1,5-naftalen-disulfonska kiselina, 2-, 3- ili 4-metilbenzensulfonska kiselina, metilsumporna kiselina, etil sumporna kiselina, dodecil sumporna kiselina, N-cikloheksilsulfamična kiselina, N-metil-, N-etil- ili N-propil-sulamična kiselina, ili druge organske kiseline, kao što je askorbinska kiselina.
U svrhu izolacije ili purifikacije isto je moguće koristiti farmaceutski neprihvatljive soli, naprimjer piktrate ili perklorate. Za terapijsku upotrebu, koriste se samo farmaceutski prihvatljive soli ili slobodni spojevi (kada se primjenjuju u obliku farmaceutskih proizvoda), a oni su gore preferirani.
U svjetlu bliskih odnosa između novih spojeva u slobodnom obliku i onih u obliku njihovih soli, uključujući te soli koje se mogu koristiti kao intermedijeri, naprimjer u purifikaciji ili identifikaciji novih spojeva, svaka referencija za slobodne spojeve gore i dolje navedene će se razumjeti kao navodi za korespondirajuće soli, kao prikladne i korisne.
Spojevi formule I i njezini N-oksidi imaju vrijedna farmakološka svojstva kao što je opisano gore i kasnije.
Učinkovitost spojeva izuma kao inhibitora aktiviteta VEGF-receptora tirozin kinaze može se prikazati kao što slijedi:
Test za aktivitet protiv VEGF-receptora tirozin kinaze. Test se izvodi upotrebom Flt-1 VEGF-receptor tirozin kinaze. Detaljni postupak je kao što slijedi: 30 μl otopine kinaze (10 ng kinaza područja Flt-1, Shibuya et al., Oncogene 5, 519-24 [1990]) u 20 mM Tris·HCl pH 7.5, 3 mM mangan diklorida (MnCl2), 3 mM magnezij klorida (MgCl2), 10 μM natrij vanadata, 0.25 mg/ml polietilen glikola (PEG) 20000, ImM ditiotreitola i 3 μg/μl poli (Glu, Tyr) 4:1 (Sigma, Buchs, Switzerland), 8 μM[33P]-ATP (0.2 μCi), 1% dimetilsulf oksida, i 0 do 100 μM spoja kojeg se ispituje inkubira se zajedno kroz 10 minuta na sobnoj temperaturi. Reakcija se završi dodavanjem 10 μl 0.25 M etilendiamintetraacetata (EDTA) pH 7. Koristeći multikanalni dispenzor (LAB SYSTEMS; USA); alikvot od 20 μl se primjeni na PVDF (=polivinil difluorid) Immobilon P membrane (Millipore, USA), preko Millipore microtiter filter manifold i spoji na vakum. Nakon kompletne eliminacije tekućine, membrana se ispere 4 puta uzastopno u kupelji koja sadržava 0.5% fosforne kiseline (H3PO4) i jedamput s etanolom inkubira se 10 minuta dok se trese, potom se prenese u Hewlett Packard TopCount Manifold i radioaktivnost mjeri nakon dodavanja 10 μl Microscint®(β-scintilation counter liguid). IC50-vrijednost određena je analizom linearne regresije kao postotak inhibicije svakog spoja u tri koncentracije (kao pravilo 0.01, 0.1, i 1 μmol). IC50-vrijednost tako se može naći sa spojevima formule I koji su u granici 0.001 do 1 μM, preferirano u granici od 0.001 do 0.1 μM.
Antitumorska učinkovitost spojeva izuma može se prikazati in vivo kao što slijedi:
In vivo učinkovitost na modelu ksenotransplantata nudo miševima: ženke BALB/c nudo miševa (8-12 tjedana šatri); novartis Animal Farm, Sisseln, Švicarska držani su u sterilnim uvjetima s vodom i hranom ad libitum. Tumori su inducirani subkutanom aplikacijom tumorskih stanica (naprimjer, linije Du 145 karcinoma prostate (ATCC br. HTB 81; vidi Cancer Research 37, 4049-58 (1978)) ili s implantacijom tumorskih fragmenata (oko 25 mg) subkutano u lijevi bok miša koristeći 13-gauge trocar igle pod Forene® anestezijom (Abbott, Švicarska). Tretiranje s test spojem počinje odmah nakon što se postigne srednji volumen od 100 mm3. Rast tumora se mjeri dva do tri puta tjedno i 24 sata nakon posljednjeg tretmana određivanjem dužine dvije perpendikularne osi. Volumne tumora se računa u skladu s objavljenim metodama (vidi Evans at al., Brit. J.Cancer 45, 466-8 [1982]). Antitumorsko djelovanje je određeno kao srednje smanjenje volumena tumora tretiranih životinja podjeljeno sa srednjim smanjenjem volumena tumora netretiranih životinja (kontrola), nakon umnožavanja sa 100, izraženo kao T/C%. Regresija tumora (dato u %) je izraženo kao najmanji srednji volumen tumora u odnosu na srednji volumen tumora na početku tretmana. Testirani spoj je apliciran dnevno kljukanjem.
Alternativne druge linijske stanice mogu se isto koristiti na isti način, naprimjer:
- MCF-7 linijske stanice adenokarcinorna prsa (ATCC br. HTB 22; vidi i J.Natl.Cancer Inst (Bethesda) 51, 1409-16 [1973]);
- MDA-MB 468 linijske stanice adenokarcinom prsa (ATCC br. HTB 132; vidi isto In Vitro 14, 911-15 [1978]);
- MDA-MB 231 linijske stanice adenokarcinoma prsa (ATCC br. HTB 26; vidi i J.Natl.Cancer Inst (Bethesda) 53, 661-74 [1974] ) ;
- Colo 205 linijske stanice karcinoma kolona (ATCC br, CCL 222; vidi i Cancer Res. 38, 1345-55 [1978]);
- HCT 116 linijske stanice karcinoma kolona (ATCC br. CCL 247; vidi i Cancer Res. 41, 1751-6 [1981]);
- DU 145 linijske stanice karcinoma prostate DU 145 (ATCC br. HTB 81; vidi i Cancer Res. 37, 4049-58 [1978]);
- PC-3 linijske stanice karcinoma prostate PC-3 (ATCC br. CRL 1435; vidi i Cancer Res. 40, 524-34 [1980]);
Inhibicija VEGF-induciranog KDR-receptora autofosforilacijom može se potvrditi s daljnjim in vitro pokusima u stanicama: transfektirane CHO stanice, koje permanentno ekspresiraju humani VEGF receptor (KDR), su zasijane u medij za kultiviranje (s 10% fetalnog seruma= FCS) i ploče za stanične kulture sa 6-bunarića i inkubirane na 37 °C pod 5% CO2 sve dok ne pokazuju 80% gustoću. Spojevi koji će biti testirani se razrijede u mediju za kulturu (bez FCS, s 0.1% bovinog albumina) i doda se u stanice. (Kontrola sadržava medij bez test spoja). Nakon dvosatne inkubacije na 37°C, doda se rekombinant VEGF; finalna koncentracija VEGF je 20 ng/ml). Nakon sljedećih pet minuta inkubacije na 37°C, stanice se isperu dvaput s led-hladnim PBS (fosfat-buferirana otopina soli) i odmah lizira u 100 μl pufera za ližu po bunariću. Lizat se potom centrifugira da se odstrane stanične jezgre, a koncentracija proteina supernatanta se odredi upotrebom komercijalne analize proteina (BIORAD). Lizat se može potom odmah koristiti, ako je potrebno, čuvati se na -20°C.
Sandwich ELISA se izvodi za mjerenje KDR-receptor fosforilacije: monoklonalna protutijela (naprimjer Mab 1495.12.14; proizvodi H.Towbin) se imobilizira na crnim ELISA pločama (OptiPlate™ HTRF-96 od Packarda). Ploče se potom operu i mjesta za vezanje preostalog slobodnog proteina zasite se s 1% BSA u PBS: Stanični lizat (20 μg proteina po bunarčiću) potom se inkubira na tim pločama preko noći na 4°C zajedno s antifosfotirosin protutijelima vezanim s alkalnom fosfatazom (PY20: AP od Transduction Laboratories). (Ploče se operu ponovo i) vežu antifosfotirozin protutijela na uhvaćeni fosforilirani receptor i potom je prikazana upotreba luminiscentnog AP substarta (CDP-star, gotovog za upotrebu, s Ernerald II; TROPIX). Luminiscencija se mjeri s Packard Top Count Microplate Scintillation Counter-om (Top CounT). Razlika između signala pozitivne kontrole (stimulirane s VEGF) i potom negativne kontrole (nestimulirane s VEGF) korespondira s VEGF induciranom KDR-receptor fosforilacijom (=100%). Aktivitet testiranog spoja je izračunat kao % inhibicije VEGF induciranog KDR receptor fosforilacije, gdje koncentracija spoj-a tako inducira pola maksimalne inhibicije definirane kao ED50 (efektivna doza za 50% inhibicije).
Spoj formule I ili njegov N-oksid inhibira različit stupanj i druge tirozin kinaze uključene u signal transdukcije koji je posredovan trofičnim faktorima, naprimjer kinaze iz Src porodice, osobito c-Src kinaze, Lck, i Fyn; isto kinaze HGF porodice, naprimjer, c-erbB2 kinaze (HER-2), c-erbB3 kinaze, c-erbB4 kinaze; inzulinu sličan faktor rasta receptor kinaze (IGF-l kinaza), osobito članovi PGDF-receptor tirozin kinaza porodice, kao što je PDGF-receptor kinaza, CSF-1-receptor kinaza, Kit-receptor kinaze i VEGF-receptor kinaze, i isto serin-treonin kinaze, sve koje igraju ulogu u regulaciji rasta i transformaciji stanica sisavaca, uključujući humane stanice.
Na osnovi tih studija, spoj formule I u skladu s izumom pokazuje učinkovitost osobito protiv poremećaja ovisnih o protein kinazi, osobito proliferativnih bolesti.
Upotrebljivost spoja formule I u tretiranju artritisa kao što je naprimjer inflamatorni reumatski ili reumatske bolesti može se prikazati kao što slijedi:
Koristi je dobro poznati model adjuvant artritis štakora (Pearson, Proc.Soc.Exp.Biol. 91, 95-101 (1956)) za testiranje anti-artritisnog djelovanja spojeva formule I, ili njegovih soli. Adjuvant artritis može se tretirati upotrebom dva različita rasporeda doziranja: ili (i) polazeći od vremena imunizacije s adjuvantom (profilaktično doziranje); ili 15 dan kada je artritički odgovor potpuno uspostavljen (terapijsko doziranje). Koristi se upotreba terapijskog rasporeda. Za komparaciju, ciklooksigenaza-2 inhibitor, kao što je S-brom-2-(4-fluorfenil)-3-[4-(metilsulfonil)fenil]tiofen ili diklofenak apliciraju se u odvojenoj skupini.
Detaljno, mužjaci Wistar štakora (5 životinja po skupini, težine aproksimativno 200 g, porijeklom Iffa Credo, Francuska) tretira se i.d. (intra-dermalno) na bazi repa s 0.1 ml mineralnog ulja koje sadržava 0.6 mg liofiliziranog temperaturom-uništenog Mycobacterium tuberculosis. Štakore se tretira s ispitivanim spojem (3, 10 ili 30 mg/kg p.o. jedanput dnevno), ili nosač (voda) od 15 do 22 dana (terapijski raspored doziranja). Na kraj u pokusa, mjeri se otok tarzalnog zgloba pomoću mico-calliper. Postotak inhibicije otoka šape kalkulira se s referentnim nosačem tretirane životinje s artritisom (0% inhibicije) i nosačem normalne tretirane životinje (100 % inhibicija).
Na osnovi tih studija, spoj formule I neočekivano je određen za tretiranje upalnih (osobito reumatskih ili reumatoidnih) bolesti.
Na osnovi njihove učinkovitosti kao inhibitora aktiviteta VEGF-receptora tirozin kinaze spoja formule I primarno inhibira rast krvnih žila i tako je, naprimjer, učinkovit protiv brojnih bolesti povezanih s dereguliranom angiogenezom, osobito bolesti uzrokovanih okularnom neovaskularizacijom, osobito retinopatije kao što su dijabetička retinopatija ili sa starosti povezana makularna degeneracija, psorijaza, hemangioblastom, kao što je haemangiom, proliferativne poremetnje inesangialnih stanica, kao što su kronične ili akutne renalne bolesti, npr. dijabetička nefropatija, maligne nefroskleroze, sindrom trombotične mikroangiopatije ili odbacivanje transplantata, ili osobito inflamatorne bolesti bubrega, kao što je glomerulonefritis, osobito mezanogioproliferativni glomerulonefritis, hemolitično-uremični sindrom, diabetička nefropatija, hipertenzivna nefroskleroza, aterom, arterijska restenoza, autoimune bolesti, akutne upale, fibrotične poremetnje (npr. ciroza jetre), dijabetes, endometrioze, kronična astma, arterijska ili post-transplantacijska ateroskleroza, neurodegenerativne poremetnje i osobito neoplastične bolesti slične leukemiji, osobito akutna limfoblastična leukemija, akutna mieloidna leukemija i kronična mieloidna leukemija, i drugi «tekući tumori», osobito oni označeni c-kit, KDR ili flt-1, i čvrsti tumori, osobito karcinom prsa, karcinom kolona, karcinom pluća (osobito karcinom pluća malih-stanica), karcinom prostate ili Kaposi-ev sarkom. Spoj formule I (ili njegov N-oksid) inhibira rast tumora i osobito je prikladan za prevenciju metastatskog širenja tumora i rasta mikrometastaza.
Spoj formule I može se aplicirati sam ili u kombinaciji s jednim ili više drugih terapijskih sredstava, moguće kombinacije terapije su u obliku fiksnih kombinacija ili aplikacija spoja izuma i jednog ili više terapijskih sredstava su nestalne ili date neovisno jedna o drugoj, ili kombinirana aplikacija fiksne kombinacije i jednog ili vise terapijskih sredstava. Osim toga spoj formule I ili uz to aplicira se posebno za terapiju tumora u kombinaciji s kemoterapijom, radioterapijom, imunoterapijom, kirurškim intervencijama, ili kombinacijom istih. Dugotrajna terapija je jednako moguća s adjuvantnom terapijom u kontekstu drugih strategija tretmana, kao što je gore opisano. Drugi mogući tretmani su terapija koja podržava pacijentov status nakon regresije tumora, ili čak kemopreventivne terapije, naprimjer na rizik pacijenta.
Terapijska sredstva za moguću kombinaciju su osobito jedan ili više citostatika ili citotoksičnih spojeva, naprimjer, kemoterapijsko sredstvo ili nekoliko odabranih iz skupine koja uključuje, ali ne limitira, inhibitor biosinteze poliamina, inhibitor protein kinaze, osobito serin/treonin protein kinaze, kao što je protein kinaza C, ili tirozin protein kinaza, kao što je receptor tirozin kinaze epidermalnog faktora rasta, citokin, negativni regulator rasta, kao što je TGF-β ili IFN-β, inhibitor aromataze, inhibitor interakcije SH2 domaina s fosforilatiranim proteinom, antiestriogeni, inhibitori topoizomeraze I, inhibitori topoizomearze II, sredstva aktivna na mikrotubule, sredstva za alkilaciju, antineoplastični antimetaboliti, spojevi platine, drugi anti-angiogeneni spojevi, agonisti gonadorelina, anti-androgeni, bifosfonati i trastuzumab.
Sa skupinom preferiranih spojeva formule I i njegovih N-oksida ovdje navedenih kasnije, definicije substituenata iz opće definicije navedene prije mogu se razborito koristiti, naprimjer, za zamjenu više općenitih definicija sa specifičnijim definicijama ili osobito s definicijama naznačenim da se preferiraju;
Osim toga, izum se odnosi na upotrebu spoj a formule I, gdje radikali i simboli imaju značenje kao što je gore definirano, ili N-oksid ili njihova farmaceutski prihvatljiva sol za proizvodnju farmaceutskog produkta za tretiranje retinopatija ili sa starosti povezanom makularnom degeneracijom.
Osim toga, izum se odnosi na postupak tretiranja neoplastičnih bolesti koje su odgovor na inhibiciju aktiviteta VEGF-receptora tirozin kinaze, koja obuhvaća aplikaciju spoja formule I ili N-oksida ili njihove farmaceutski prihvatljive soli, gdje radikali i simboli imaju značenje kao što je definirano gore, u učinkovitoj količini protiv navedenih bolesti, toplokrvnih životinja za koje se zahtjeva tretman.
Osim toga, izum se odnosi na postupak za tretiranje retinopatija ili makularne degeneracije povezane sa starosti, koja obuhvaća aplikaciju spoja I ili N-oksida ili njihovih farmaceutski prihvatljivih soli, gdje radikali i simboli imaju značenje kao što je definirano gore, u učinkovitoj količini protiv navedenih bolesti, toplokrvnih životinja za koje se zahtjeva tretman.
Izum se posebno odnosi na spoj formule I, gdje
R1predstavlja H ili niži alkil,
R2 predstavlja H ili niži alkil,
R3 predstavlja trifluormetil, i
X je O,
na N-oksidu ili njegovom tautomeru,
i na soli takvog spoja, njegovom N-oksidu ili tautomeru.
Preferirano, izum se posebno odnosi na spoj formule I, gdje
R1 predstavlja H ili metil,
R2 predstavlja H ili metil,
R3 predstavlja trifluormetil, i
X je O,
na njegovom tautomeru,
1 na soli takvog spoja ili tautomeru.
Preciznije, prednost je data sljedećim spojevima formule I:
2-[[6-metoksi-3-piridinil]metil]amino-N-[3-(trifluormetil)fenil]benzamid hidroklorid sol,
2-[[6-metoksi-3-piridinil]metil]amino-N-[2-metil-3-(trifluormetil)fenil]benzamid,
2-[[(1,6-dihidro-6-okso-3-piridinil]metil]amino-N-[3-(trifluormetil)fenil]benzamid,
2-[[(1,6-dihidro-6-okso-3-piridinil]metil]amino-N-[2-metil-3-(trifluormetil)fenil]benzamid,
i njegove tautomere, ili soli takvog spoja ili njegov tautomer.
Spoj izuma može se proizvesti postupkom tako, iako nije primjenjen do sada za nove spojeve prezentiranog izuma, koji su poznati per se, osobito postupak karakteriziran time da za sintezu spoja formule I gdje ri predstavlja niži alkil a preostali simboli R2 i R3 su kao što je definirano za spoj formule I, spoj formule II
[image]
gdje R2 i R3 su kao što je definirano za spoj formule I, je reagirala s karbonil spojem formule II
[image]
gdje X predstavlja O ili S a R1 je niži alkil u prisutnosti sredstva za redukciju,
gdje polazni spojevi formule II i III mogu isto biti prisutni s funkcionalnom skupinom u zaštićenom obliku, ako je neophodno, i/ili u obliku soli, opskrbljena sol-formirajuća skupinom prisutna je, a moguća je reakcija u obliku soli.
gdje su odstranjene sve zaštićene skupine u zaštićenom derivatu spoja formule I:
i ako se zahtjeva, spoj formule I koji se može dobiti je pretvoren u drugi spoj formule I ili njegov N-oksid, slobodni spoj formule I je pretvoren u sol, sol formule I koja se može dobiti je pretvorena u slobodan spoj ili drugu sol, i/ili smjesu izomernih spojeva formule I odvojene u pojedine izomere.
Detaljni opis reduktivne alkilacije:
U detaljnijem opisu dolje navedenog procesa, R1, R2, R3 i X su kao što je definirano za spojeve formule I, ukoliko nije drugačije navedeno.
Karbonil spojevi formule III mogu isto biti prisutni u obliku reaktivnih derivata; međutim, preferiraju se slobodni aldehidi ili ketoni.
Reaktivni derivati spojeva formule III su, naprimjer, odgovarajući adukti sulfita ili posebno semiacetali, acetali, semiketali ili ketali spojeva formule III s alkoholima, naprimjer nižim alkanolima; ili tioacetali i tioketali spojeva formule III s merkaptanima, naprimjer niži alkansulfidi.
Reduktivna alkilacija preferirano se izvodi s hidrogenacijom u prisutnosti katalizatora, osobito plemenitog metala kao katalizatora, kao što je platina ili osobito paladij, koji je preferirano vezan na nosač, kao što je ugljik, ili katalizator teški metal, kao što je Raney nikal, na normalnom tlaku ili na tlaku od 0.1 do 10 MegaPaskal (MPa), ili s redukcijom pomoću kompleks hidrida, kao što su borhidridi, osobito alkali metal cijanoborhidridi, naprimjer natrij cijanoborhidrid, u prisutnosti prikladne kiseline, preferirano relativno slabih kiselina, kao što su niže alkankarboksilne kiseline, osobito octena kiselina, ili sulfonska kiselina, kao što je p-toluensulfonska kiselina; u uobičajenom otapalu, naprimjer alkoholima, kao što je metanol ili etanol, ili eterima, naprimjer cikličnim eterima, kao što je tetrahidrofuran, u prisutnosti ili odsutnosti vode.
Zaštitne skupine
Ako jedna ili više drugih funkcionalnih skupina, naprimjer karboksi, hidroksi, amino, ili merkapto su ili trebaju biti zaštićene u spoju formule II ili III, zbog toga što ne trebaju sudjelovati u reakciji, to su one skupine koje se uobičajeno koriste u sintezi peptidnih spojeva, i isto cefalosporini i penicilini, kao što su derivati nukleinskih kiselina i šećeri.
Zaštitne skupine mogu biti već prisutne u prekursorima i trebaju zaštiti funkcionalne skupine koje se tiču neočekivanih sekundarnih reakcija, kao što su acilacije, eterifikacije, esterifikacije, oksidacije, solvolize, i slične reakcije. Karakteristično je za zaštitne skupine da one same pružaju gotove, tj. bez neželjenih sekundarnih reakcija, za odstranjivanje, uobičajene solvolize, redukcije, fotolize i isto djelovanje enzima, naprimjer pod uvjetim analognim fiziološkim uvjetima, i da oni nisu prisutni u finalnom produktu. Specijalisti znaju, ili mogu brzo utvrditi, koje zaštitne skupine su prikladne u reakcijama navedenim prije i poslije.
Zaštita takvih funkcionalnih skupina s takvim zaštitnim skupinama, zaštitne skupine one same, i njihove reakcije odstranjivanja su opisane naprimjer u standardnim referentnim dijelovima, kao u J.F.W- McOmie, «Protective Groups in Organic Chemistry», Plenum Press, london and New York 1973, u T.W.Greene, «Protective Groups in Organic Synthesis», Wiley, New York 1981, in «The Peptides»; Volume 3 (editors: E.Gross and J.Meienhofer), Academic Press, London and New York 1981; u «Methoden der organischen Chemie» (Methods of organic chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.D.Jakubke and H.Jescheit, «Aminosauren, Peptide, Proteine» (Amino acids, peptides, proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, i u Jochen Lehmann, «Chemie der Kohlenhydrate: Monosaccaride und Derivate» (Chemistry of carbohydrates: monosaccharides and derivatives), Georg Thieme Verlag, Stuttgart 1974.
Dodatne faze procesa
Soli spojeva formule I sa skupinom koja formira sol može se proizvesti na način per se. Soli dodanih kiselina spojeva formule I može se tako dobiti tretiranjem s kiselinom ili bez odgovarajućeg reagensa za mjeri janje aniona. Sol s dvije molekule kiseline (naprimjer dihalogenid spoja formule I) može isto biti pretvoren u sol s jednom molekulom kiseline po spoju (naprimjer monohalogenid); to se može napraviti zagrijavanjem do tališta, ili naprimjer zagrijavanjem krutine pod visokim vakuumom na povišenoj temperaturi, naprimjer od 130 do 170 °C, jedna molekula kiseline će biti izbačena po molekuli spoja formule I.
Soli se uobičajeno pretvaraju u slobodne spojeve, tj. tretiranjem s odgovarajućim bazičnim sredstvima, naprimjer s alkali metal karbonatima, alkali metal hidrogenkarbonatima, ili alkali metal hidrokisde, obično kalij karbonat ili natrij hidroksid.
Amidi antralinične kiseline formule I gdje R1 predstavlja niži alkil, a preostali simboli R2 i R3 su definirani za spojeve formule I, dobivene reakcijom spojeva formule II i formule III, mogu dalje reagirati u skladu sa sljedećim postupkom koji osigurava amide antranilične kiseline formule I gdje R1 predstavlja H, Amidi antranilične kiseline formule I gdje R1 predstavlja niži alkil je tretiran s trimetilsilil jodidom kroz 20 do 35 sati na temeparturi između 45°C i 70°C u prikladnom otapalu, tj. halogeniranom alkanu, kao što je kloroform, po izboru slijedi tretman s metanolom.
Opći uvjeti proizvodnje
Sve faze procesa opisanog ovdje mogu se izvesti pod poznatim uvjetima reakcije, preferira se pod onim specifično navedenim, u odsutnosti ili uobičajenim u prisutnosti otapala ili razrjeđivača, preferiraju se takvi kao što su korišteni inertni reagensi i koji su sposobni rastopiti ih, u odsutnosti ili prisutnosti katalizatora, sredstva za kondenziranje ili sredstva za neutraliziranje, naprimjer izmjenjivača iona, tipičan izmjenjivač kationa, naprimjer u H+ obliku, ovisno o tipu reakcije i/ili reaktanta u redukciji, normalna ili povišena temperatura, naprimjer u granicama između -100 °C do oko 190 °C, preferirano od oko -80 °C do oko 150 °C, naprimjer -80 do -60 °, na sobnoj temperaturi, na -20 do -40 °C na točki vrenja korištenog otapala, pod atmosferskim tlakom ili u zatvorenoj posudi, gdje pod određenim tlakom, i/ili u inertnoj atmosferi, naprimjer pod argonom ili dušikom.
Soli mogu biti prisutne u svim polaznim spojevima, ako oni sadržavaju skupine koje formiraju soli. Soli mogu isto biti prisutne tijekom reakcije takvih spojeva, koji osiguravaju da reakcija nije jako burna.
Otapala od kojih se mogu odabrati koja su prikladna za reakciju predmeta uključuje naprimjer vodu, estere, tipične niže alkil-niže alkanoate, npr. dietil acetate, etere, tipične alifatske etere, npr. dietileter, ili ciklične etere, npr. tetrafuran, tekuće aromatske hidrokarbonate, tipični benzen ili toluen, tipični metanol, etanol ili 1- ili 2-propanol, nitrile, tipične acetonitrile, halogenirane hidrokarbonate, tipične diklormetane, amide kiselina, tipične dimetilformamide, baze, tipične heterociklične baze dušika, npr. piridine, karboksilne kiseline, tipične niže alkanokarboksilne kiseline, npr. octena kiselina, anhidridi karboksilne kiseline, tipični anhidridi nižih alkani kiselina, npr. octeni anhidrid, ciklični, linearni, ili razgranati hidrokarboni, tipični cikloheksan, heksan ili izopentan, ili smjesa tih otapala, npr. vodena otopina, bez drugih stanja opisanih u postupku. Takve smjese otapala mogu se koristiti u proizvodnji, naprimjer kromatografijom ili distribucijom.
Spojevi formule I, uključujući njihove soli, se isto mogu dobiti u obliku hidrata, ili njihovih kristala mogu sadržavati naprimjer otapalo korišteno za kristalizaciju (prisutni kao solvati).
U preferiranom ostvarenju, spoj formule I je proizveden u skladu s ili analogno procesima i fazama procesa definiranim u Primjerima.
Doziranje aktivne tvari ovisi o brojnim faktorima uključujući tip, vrstu, dob, tjelesnu masu, spol i medicinsko stanje pacijenta; težini stanja koje će biti tretirano, putu aplikacije; funkciji bubrega i jetre pacijenta; i osobito o spoju koji će biti korišten. Liječnik, kliničar ili veterinar koji ordinira može stvarno determinirati i propisati učinkovitu količinu lijeka zahtjevanog za sprečavanje, kontroliranje ili zaustavljanje uvjeta progresa. Optimalno određivanje u provođenju koncentracije lijeka unutar granica rezultata učinkovitosti bez toksičnih propisanih zahtjeva bazira se na kinetici raspoloživosti lijekova na ciljnom mjestu. To uključuje razmatranje distribucije, ekvilibrija i eliminacije lijeka.
Izum se odnosi i na farmaceutske kompozicije koje obuhvaćaju učinkovitu količinu, osobito učinkovitu količinu u tretiranju jednog od gore navedenih poremećaja, amida antranilične kiseline formule I ili N-oksida ili njegovog tautomera zajedno s farmaceutski prihvatljivim nosačima koji su odgovarajući za topičku, enteralnu, naprimjer oralnu ili rektalnu, ili parenteralnu aplikaciju a mogu biti anorganski ili organski čvrsti ili tekući.
Koristi se za oralnu aplikaciju osobito tablete ili želatinozne kapsule koje obuhvaćaju aktivnu tvar zajedno s diluentom, naprimjer laktoza, dekstroza, manitol, i/ili glicerol, i/ili lubrikante i/ili polietilen glikol. Tablete mogu sadržavati veziva, naprimjer magnezij aluminij silikat, škrob, kao što je kukuruzni, pšenični ili rižin škrob, želatina, metilceluloza, natrij karboksimetilceluloza i/ili polivinilpirolidon, i, ako se zahtjeva, dezintegratore, naprimjer, škrob, agar, algininska kiselina ili njezine soli, ako što je natrij alginat, i/ili eferescentna smjesa, kao adsorbenti, boje, korektori okusa, zaslađivači. Isto je moguće koristiti farmakološki aktivne spojeve prezentiranog izuma u obliku sastava koji se mogu parentaralno aplicirati ili u obliku otopina za infuziju. Farmaceutski sastavi mogu se sterilizirati i/ili obuhvaćati eksipijense, naprimjer konzervanse, stabilizatore, sredstva za vlaženje i/ili emulgatore, solubilizatore, soli za regulaciju osmotskog tlaka i/ili pufere. Prezentirani farmaceutski sastavi, koji mogu, ako se zahtjeva, sadržavati druge farmakološki aktivne tvari proizvedene na način poznat per se, naprimjer pomoću konvencionalnog miješanja, granulacije, izradom, rastapanjem ili postupkom liofilizacije, i sadržava aproksimativno od 1% do 95%, osobito od aproksimativno 1% do aproksimativno 20%, aktivne(ih) tvari.
Osim toga, izum se odnosi na farmaceutske sastave za tretiranje tumora toplokrvnih životinja, uključujući ljude, obuhvaća antitumoralne učinkovite doze spoja formule I kao što je gore opisano ili farmaceutski prihvatljive soli kao što je spoj zajedno s farmaceutskim nosačem.
Dodatno, prezentirani izum osigurava amide antranilične kiseline formule I ili njezine N-okside ili tautomer, ili farmaceutski prihvatljive soli kao što je spoj, za upotrebu u postupku za tretiranje ljudi i životinja.
Prezentirani izum se isto odnosi i na upotrebu amida antranilične kiseline formule I ili na njezine N-okisde ili tautomer, ili farmaceutski prihvatljivu sol kao što je spoj, za proizvodnju farmaceutskog produkta za tretiranje neoplastičnih bolesti, retinopatije ili makularne degeneracije povezane sa dobi.
Pored toga, prezentirani izum prikazuje postupak za tretiranje neoplastičnih bolesti koje odgovaraju na inhibiciju aktivnosti VEGF-receptora tirozin kinaze, koji obuhvaća aplikaciju amida antranilične kiseline formule I ili njezinog N-oksida ili tautomera, ili farmaceutski prihvatljive soli kao što je amid antranilične kisliene, njezini N-okisd ili njezin tautomer, a učinkovitu količinu protiv navedenih bolesti, toplokrvnih životinja kod kojih se zahtjeva takav tretman.
Polazni materijali
Novi polazni materijali i/ili njihovi intermedijeri, kao što su postupci za njihovu proizvodnju, su isto predmet ovog izuma. U preferiranom ostvarenju, takvi polazni materijali se koriste a uvjeti reakcije su odabrani tako da su sposobni za davanje preferiranih spojeva.
Polazni materijali formule III, IV i V su poznati, komercijalno dostupni, ili se mogu sintetizirati analogno u skladu s postupcima poznatim u struci.
Naprimjer spoj formule II može se proizvesti redukcijom nitro spoja formule IV,
[image]
gdje R2 i R3 imaju značenje dato za formulu I.
Redukcija preferirano se provodi u prisutnosti odgovarajućeg sredstva za redukciju, kao što je kositar(II) klorid ili vodik u prisutnosti odgovarajućeg katalizatora, ako što je Raney nikl (tada se preferira upotreba vodika pod tlakom, npr. između 2 i 20 bara) ili PtO2, u odgovarajućem otapalu, npr. alkoholu, kao što je metanol. Temperatura reakcije je preferirano između 0 i 80 °C, osobito 15 do 30 °C.
Nito spoj formule IV se može dodati u reakciju za aktiviranje derivata kiseline formule VI,
[image]
gdje Y je halogen ili druga odgovarajuća ostatna skupina, koja je reagirala s aminom formule V,
[image]
gdje R2 i R3 su kao što je definirano u formuli I, npr. u prisutnosti sredstva za spajanje, kao što je dicikloheksilkarbodiimid, na temperaturi između 0°C i 50 °C, preferirano na sobnoj temperaturi.
Svi preostali polazni materijali su poznati, sposobni da budu proizvedeni u skladu s poznatim postupcima, ili se mogu komercijalno dobiti; osobito, se mogu proizvesti upotrebom postupka opisanim u Primjerima.
U proizvodnji polaznih materijala, postoje funkcionalne skupine koje ne trebaju participirati u reakciji, ako je potrebno zaštićene su. Preferirane zaštitne skupine, njihovo uvođenje i njihovo odstranjivanje je opisano u «zaštitne skupine» ili u Primjerima.
Svi preostali materijali su poznati, sposobni su za proizvodnju u skladu s poznatim postupcima, ili se komercijalno mogu nabaviti; osobito, oni se mogu proizvesti upotrebom postupaka opisanih u Primjerima.
Sljedeći primjeri su dati za ilustraciju izuma bez ograničenja izuma i njegovih ciljeva.
Temperature se mjere u stupnjevima celzijusa (°C). Nedostatak drugih indikacija, reakcije se izvode na sobnoj temperaturi.
PRIMJERI
Referentni Primjer 1
2-[[6-metoksi-3-piridinil]metil]amino-N-[4-brom-3-(trifluor-metil)fenil]benzamid (ne zahtjeva se)
Natrij cianoborhidrid (8.80 g 95%, 133 mmol) se doda u porcijama preko 30 minuta uz miješanje smjese octene kiseline (3.8 mL), 6-metoksi-3-piridinkarboksaledehid (Pluka, Buchs, Switzerland; 7.80 g, 57 mmol) i 2-amino-N-(4-brom-3-trifluormetilfenil)-benzamid (faza 1.2; 13.65 g, 38 mmol) u metanolu (380 mL) na 25 °C. Smjesa se miješa kroz 16 sati. Otapalo se evaporira pod reduciranim tlakom da se dobije ostatak koji se tretira sa zasićenom vodenom otopinom natrij hidrogen karbonata (500 mL) i ekstarhira s diklormetanom (3×150 mL). Spojeni ekstarkti se osuše (Na2SO4), filtrira a otapalo se evaporira pod reduciranim tlakom da bi se dobio sirovi produkt koji se purificira kolonskom koromatografijom na silika gelu, eluent 5% etil acetat u diklormetanu i redistilira se iz dietileter-heksan da se dobije imenovani spoj kao bež kristalna krutina, t.t. 101-103 °C.
Faza 1.1: 2-nitro-N-(4-brom-3-trifluormetilfenil)benzamid
Otopini 3-amino-6-brombenzotrifluorid (Fluka, Buchs, Switzerland; 24.0 g, 100 mmol) u etil acetatu (240 mL) se doda uz miješanje vodena otopina natrij hidroksida (110 mL IM) na sobnoj temperaturi. Tako izmješana otopina se tretira s kap po kap tijekom 30 minuta s otopinom 2-nitrobenzoil kloridom (Fluka, Buchs, Switzerland; 14.5 mL, 110 mmol) u etil acetatu (150 mL). Nastala smjesa se miješa kroz 30 minuta na temperaturi ambijenta. Smjesa se ekstrahira s etil acetatom (3×100 mL) a spojeni ekstrakt se kasnije ispere s klorovodičnom kiselinom (2×100 mL 2M), vodom (2×100 mL), zasićenom vodenom otopinom natrij klorida (1×100 mL), osuši (MgSO4), filtrira a otapalo se evaporira pod reduciranim tlakom da se dobije sirovi produkt koji se purificira rekristalizacijom iz etil acetat-heksan da se dobije imenovani spoj kao bež čvrsti kristali, t.t. 157-158 °C
Faza 1.2: 2-amino-N-(4-brom-3-trifluormetilfenil)benzamid
Otopina 2-nitro-N-(4-brom-3-trifluormetilfenil)benzamid (intermedijer 1a; 32 g, 82 mmol) u metanolu (1000 mL) se hidrogenira na atmosferskom tlaku preko Raney nikla (6 g) na 21 °C. Kalkulirana količina vodika se postigne nakon 7 sati. Smjesa se filtrira a otapalo se evaporira pod reduciranim tlakom da se dobije sirovi produkt koji se purificira rekristalizacijom iz dietileter-heksana da se dobije imenovani spoj kao čvrsti bezbojni kristali, t.t. 142-144 °C.
Primjer 2
2-[[6-metoksi-3-piridinil]metil]amino-N-[3-(trifluormetil)fenil]benzamid hidroklorid sol
Imenovani spoj se proizvodi postupkom analognim onom opisanom u Primjeru 1 koristeći intermedijer iz faze 2.2 i 6-metoksi-3-piridinkarboksaldehid (Fluka, Buchs, Switzerland); 1.1. 133-135 °C.
Faza 2.1: 2-nitro-N-[3-(trifluormetil)fenil]benzamid
Imenovani spoj se proizvodi analogno fazi 1.1 uz to da se koristi 3-(trifluormetil)-benzenamin (Aldrich, Buchs, Switzerland); t.t. 134-135 °C.
Faza 2.2: 2-amino-N-[(3-trifluormetil)fenil]benzamid
Imenovani spoj se proizvodi analogno fazi 1.2 uz to da se koristi 2-nitro-N-[(3-trifluormetil)fenil]benzamid (faza 2.1); 132-133 °C.
Primjer 3
2-[[β-metoksi-3-piridinil]metil]amino-N-[2-metil-3-(trifluormetil)fenil]-benzamid
Imenovani spoj se proizvodi postupkom analognim onom opisanom u Primjeru 1 uz korištenje intermedijera iz faze 3.2 i 6-metoksi-3-piridinkarboksaldehid (Aldrich, Buchs, Switzerland); t.t. 134-135 °C.
Faza 3.1: 2-nitro-N-[2-metil-3-(trifluormetil)fenil]benzamid
Imenovani spoj se proizvodi analogno fazi 1.1 uz korištenje 2-metil-3-(trifluormetil)benzenamin (Fluorochem, Derbyshire, England) ; 1.1. 188-189 °C.
Faza 3.2: 2-amino-N-[2-metil-(3-trifluormetil)fenil]benzamid
Imenovani spoj se proizvodi analogno fazi 1.2 uz korištenje 2-nitro-N-[2-metil-3-(trifluormetil)fenil]benzamin (faza 2.1); t .t. 128-129ºC,
Referentni Primjer 4
2-[[(1,6-dihidro-6-okso-3-piridinil)metil]amino]-N-[4-propinil-3-(trifluorrnetil)fenil]benzamid (ne zahtjeva se)
Smjesa 2-[[6-metoksi-3-pirinil]metil]amino-N-[4-(1-propinil)-3-(trifluormetil)-fenil]benzamid (faza 4.1; 1.10 g, 2.5 mmol) i trimetilsilil jodida (Fluka, Buchs, Switzerland; 1.0 mL, 7.5 mmol) u kloroformu (30 mL) miješa se na 60 °C kroz 16 sati u atmosferi argona. Ohlađena smjesa se potom tretira s metanolom (2 mL) i miješa na sobnoj temeparturi kroz 10 minuta. Otapalo se evaporira pod reduciranim tlakom a ostatak se tertira s vodenom otopinom amonijaka (100 rnL 5%) i ekstahira Sa etil acetatom (3×100 mL). Spojeni ekstrakti se isperu sa zasićenom vodenom otopinom natrij klorida (50 mL), osuši (MgSO4) , filtrira se, a otapalo se evaporira pod reduciranim tlakom pa se dobije sirovi produkt koji se purificira kolonskom kromatografijom na silika gelu, eluent etilacetat i kristalizirani oblik iz vrućeg etil acetat-heksan da se dobije imenovani spoj kao bezbojni čvrsti kristali; t.t. 208-212 °C.
Faza 4.1: 2-[[6-metoksi-3-piridinil]metil]amino-N-[4-(1-propinil)-3-(trifluormetil)-fenil]benzamid
Uz miješanje otopine 2-[[6-metoksi-3-piridinil]metil]amino N-[4-brom-3-(trifluormetil)-fenil]benzamid (Referentni Primjer 1; 3.98 g, 8.3 mmol) u suhom toluenu (200 mL) očisti se s argonom kroz 20 minuta na 25 °C. Tributil-1-propinilstanan (4.1 g 80%, 9.96 mmol) i tetrakis(trifenilfosfin)paladij (O) (260 mg) se potom doda a nastala smjesa se zagrije na 100 °C kroz 17 sati u atmosferi argona. Smjesa se ohladi, tretira s vodenom otopinom natrij hidroksida (85 mL 0.1 M) i očisti s zrakom kroz 2 sata. Nastala smjesa se ekstrahira s etil acetatom (3×100 mL). Organska faza se kasnije ispere vodom (2×40 mL) i zasićenom vodenim natrij kloridom (1×40 mL), osuši (Na2SO4), filtrira i otapalo se evaporira pod reduciranim tlakom da se dobije sirovi produkt koji se purificira kolonskora kromatografijom na silika gelu, eluent 33% etil acetat i heksan i rekristalizira iz dietileter-heksan da se dobije imenovani spoj kao svjetlo-žuti čisti kristali; 1.1. 123-124 °C.
Primjer 5
2-[[(1,6-dihidro-6-okso-3-piridinil)metil]amino]-N-[3-(trifluormetil)fenil]benzamid
Imenovani spoj se proizvodi postupkom analognim onom opisanom u Primjeru 4 s time da se koristi 2-[[6-metoksi-3-piridinil]metil]amino-N-[3-(trifluormetil)fenil]benzamid (Primjer 2); t.t. 171-172 °C.
Primjer 6
2-[[(1,6-dihidro-6-okso-3-piridinil)metil]amino]-N-[2-metil-3-(trifluormetil)fenil]benzamid
Imenovani spoj se proizvodi postupkom analognim onom opisanom u Primjeru 8 s time da se koristi 2-[[6-metoksi-3-piridinil]metil]amino-N-[2-metil-3-(trifluormetil)fenil] benzamid (Primjer 3); t.t. 191-192 °c.
Primjer 7
mekane kapsule
5000 mekanih želetinoznih kapsula, svaka sadržava 0.05 g aktivne tvari jednog od spojeva formule I navedene u prethodnim primjerima, koje su proizvedene kao što slijedi:
Sastav
Aktivna tvar 250 g
Lauroglikol 2 litre
Postupak proizvodnje: Praškasta aktivna tvar se suspendira u Laurilglikolu® (propilen glikol laurat, Gattefosse S.A., Saint Priest, France) i stavi se u vlažnu spravu kojom se pretvara u prašinu za proizvodnju veličine čestica od oko 1 do oko 3 μm. Potom se 0.419 g smjese uvede u mekane kapsule upotrebom stroja za punjenje kapsula.
Claims (10)
1. Amid antranilične kiseline formule I;
[image]
naznačen time, da
R1predstavlja H ili niži alkil,
R2 predstavlja H ili niži alkil,
R3 predstavlja perfluor niži alkil, i
X je O ili S,
ili njegov N-oksid ili tautomer,
ili soli amida antranilične kiseline, njezin N-oksid ili tautomer.
2. Amidi antranilične kiseline formule I u skladu sa zahtjevom 1, naznačeni time, da
R1predstavlja H ili niži alkil,
R2 predstavlja H ili niži alkil,
R3 predstavlja trifluormetil, i
X je O,
ili njegov N-oksid ili tautomer,
ili soli amida antranilične kiseline, njezin N-oksid ili tautomer.
3. Amidi antranilične kiseline formule I u skladu sa zahtjevom 1, naznačeni time, da
R1predstavlja H ili metil,
R2 predstavlja H ili metil,
R3 predstavlja trifluormetil, i
X je O,
ili tautomer,
ili soli amida antranilične kiseline, njezin N-oksid ili njegov tautomer.
4. Amid antralinične kiseline formule I u skladu sa zahtjevom 1, naznačen time, da su odabrani od
2-[[6-metoksi-3-piridinil]metil]amino-N-[3-(trifluormetil) fenil]benzamid hidroklorid sol,
2-[[6-metoksi-3-piridinil]metil]amino-N-[2-metil-3-(trifluormetil)fenil]benzamid,
2-[[(1,6-dihidro-6-okso-3-piridinil]metil]amino-N-[3-(trifluormetil)fenil]benzamid, i
2-[[(1,6-dihidro-6-okso-3-piridinil]metil]amino-N-[2-metil-3-(trifluormetil)fenil]benzamid,
ili njihov N-oksid ili tautomer,
ili soli amida antranilične kiseline, njezin N-oksid ili tautomer,
5. Amid antranilične kiseline formule I u skladu sa bilo kojim od zahtjeva 1 do 4, ili njegovim N-oksidom ili tautomerom, ili farmaceutski prihvatljivom soli takvog spoja, naznačen time, da se koristi u postupku za tretiranje ljudi i životinja.
6. Upotreba amida antralinične kiseline formule 1 naznačena time, da radikali i simboli imaju značenje kao što je definirano u zahtjevu 1, ili njegovom N-oksidu ili tautomeru, ili farmaceutski prihvatljiva sol takvog spoja, za proizvodnju farmaceutskog produkta za tretiranje neoplastičnih bolesti.
7. Upotreba amida antralinične kiseline formule 1 naznačena time, da radikali i simboli imaju značenje kao što je definirano u zahtjevu 1, ili njegovom N-oksidu ili tautomeru, ili farmaceutski prihvatljiva sol takvog spoja, za proizvodnju farmaceutskog produkta za tretiranje retinopatije ili makularne degeneracije povezane sa starosti.
8. Postupak za tretiranje neoplastičnih bolesti koje su odgovor na inhibiciju aktivnosti VEGF-receptora tirozin kinaze, obuhvaća aplikaciju amida antralinične kiseline formule I ili njezinog N-oksida ili tautomera, naznačen time, da radikali i simboli imaju značenje kao u zahtjevu 1, u učinkovitoj količini protiv navedenih bolesti, za toplokrvne životinje kod kojih se zahtjeva takav tretman.
9. Farmaceutski proizvod, naznačen time, da sadržava amid antralinične kiseline formule I u skladu s svakim od zahtjeva 1 do 4, ili njegovim N-oksidom ili tautomerom, ili farmaceutski prihvatljiva sol takvog spoja, ili njegovi hidrati ili solvati i najmanje jedan farmaceutski prihvatljiv nosač.
10. Postupak proizvodnje amida antralinične kiseline formule I
[image]
naznačen time, da R1 predstavlja niži alkil a preostali simboli R2 i R3 su definirani u zahtjevu 1, gdje je spoj formule II
[image]
gdje su R2 i R3 definirani za spoj formule I, reagira s karbonil spoj em formule III
[image]
gdje X predstavlja O ili S, a ri je niži alkil u prisutnosti sredstva za redukciju,
gdje polazni spojevi formule II i III mogu isto biti prisutni s funkcionalnim skupinama u zaštićenom obliku, ako je neophodno, i/ili u obliku soli, osigurano sa sol-formirajućom skupinom i reakcija za formiranje soli je moguća;
gdje sve zaštićene skupine u zaštićenom derivatu spoja formule I su odstranjene;
i, ako se zahtjeva, spoj formule I koji je moguće dobiti se pretvori u drugi spoj formule I ili njegov N-oksid, slobodni spoj formule I se pretvori u sol, sol koja se može dobiti od spoja formule I je pretvorena u slobodni spoj ili drugu sol, i/ili smjesu izomeričnih spojeva formule I se odvoji u pojedine izomere.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126902.6A GB0126902D0 (en) | 2001-11-08 | 2001-11-08 | Organic compounds |
PCT/EP2002/012444 WO2003040102A1 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20040411A2 true HRP20040411A2 (en) | 2005-04-30 |
Family
ID=9925448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20040411A HRP20040411A2 (en) | 2001-11-08 | 2004-05-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
Country Status (28)
Country | Link |
---|---|
US (2) | US7091224B2 (hr) |
EP (1) | EP1446382B1 (hr) |
JP (1) | JP2005511602A (hr) |
KR (1) | KR100602977B1 (hr) |
CN (1) | CN1300113C (hr) |
AT (1) | ATE496889T1 (hr) |
AU (1) | AU2002351909B2 (hr) |
BR (1) | BR0213970A (hr) |
CA (1) | CA2463968C (hr) |
CO (1) | CO5580823A2 (hr) |
DE (1) | DE60239073D1 (hr) |
ES (1) | ES2360283T3 (hr) |
GB (1) | GB0126902D0 (hr) |
HR (1) | HRP20040411A2 (hr) |
IL (1) | IL161747A0 (hr) |
MX (1) | MXPA04004391A (hr) |
NO (1) | NO327231B1 (hr) |
NZ (1) | NZ532590A (hr) |
PE (1) | PE20030714A1 (hr) |
PL (1) | PL368416A1 (hr) |
PT (1) | PT1446382E (hr) |
RU (1) | RU2318811C2 (hr) |
SA (1) | SA02230412B1 (hr) |
TW (1) | TWI260222B (hr) |
UA (1) | UA77446C2 (hr) |
WO (1) | WO2003040102A1 (hr) |
YU (1) | YU36004A (hr) |
ZA (1) | ZA200402940B (hr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
CA2588633A1 (en) | 2004-12-07 | 2006-06-15 | Toyama Chemical Co., Ltd. | Novel anthranilic acid derivative or salt thereof |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
CN101265274B (zh) * | 2007-02-16 | 2013-09-04 | 中国医学科学院药物研究所 | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 |
CA2734551A1 (en) | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
GB201322538D0 (en) | 2013-06-21 | 2014-02-05 | Immusmol Sas | Method for detecting small molecules in a sample |
CN107954893A (zh) * | 2017-11-28 | 2018-04-24 | 兰州纬寰生物科技有限公司 | 邻氨基苯甲酰胺衍生物及制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
-
2001
- 2001-11-08 GB GBGB0126902.6A patent/GB0126902D0/en not_active Ceased
-
2002
- 2002-07-11 UA UA20040403226A patent/UA77446C2/uk unknown
- 2002-11-02 SA SA02230412A patent/SA02230412B1/ar unknown
- 2002-11-06 TW TW091132669A patent/TWI260222B/zh active
- 2002-11-06 PE PE2002001080A patent/PE20030714A1/es not_active Application Discontinuation
- 2002-11-07 JP JP2003542148A patent/JP2005511602A/ja active Pending
- 2002-11-07 DE DE60239073T patent/DE60239073D1/de not_active Expired - Lifetime
- 2002-11-07 AU AU2002351909A patent/AU2002351909B2/en not_active Ceased
- 2002-11-07 KR KR1020047007040A patent/KR100602977B1/ko not_active IP Right Cessation
- 2002-11-07 NZ NZ532590A patent/NZ532590A/en not_active IP Right Cessation
- 2002-11-07 PT PT02787595T patent/PT1446382E/pt unknown
- 2002-11-07 IL IL16174702A patent/IL161747A0/xx unknown
- 2002-11-07 RU RU2004117543/04A patent/RU2318811C2/ru not_active IP Right Cessation
- 2002-11-07 WO PCT/EP2002/012444 patent/WO2003040102A1/en active IP Right Grant
- 2002-11-07 BR BR0213970-7A patent/BR0213970A/pt not_active IP Right Cessation
- 2002-11-07 CA CA2463968A patent/CA2463968C/en not_active Expired - Fee Related
- 2002-11-07 EP EP02787595A patent/EP1446382B1/en not_active Expired - Lifetime
- 2002-11-07 CN CNB028222091A patent/CN1300113C/zh not_active Expired - Fee Related
- 2002-11-07 MX MXPA04004391A patent/MXPA04004391A/es active IP Right Grant
- 2002-11-07 US US10/494,591 patent/US7091224B2/en not_active Expired - Fee Related
- 2002-11-07 YU YU36004A patent/YU36004A/sh unknown
- 2002-11-07 PL PL02368416A patent/PL368416A1/xx not_active Application Discontinuation
- 2002-11-07 AT AT02787595T patent/ATE496889T1/de active
- 2002-11-07 ES ES02787595T patent/ES2360283T3/es not_active Expired - Lifetime
-
2004
- 2004-04-19 ZA ZA200402940A patent/ZA200402940B/en unknown
- 2004-05-07 HR HR20040411A patent/HRP20040411A2/hr not_active Application Discontinuation
- 2004-05-12 CO CO04043909A patent/CO5580823A2/es not_active Application Discontinuation
- 2004-05-26 NO NO20042187A patent/NO327231B1/no not_active IP Right Cessation
-
2006
- 2006-03-14 US US11/374,720 patent/US7482369B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7482369B2 (en) | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | |
US6448277B2 (en) | VEGF receptor tyrosine kinase inhibitors | |
JP2003520853A (ja) | 2−アミノ−ニコチンアミド誘導体 | |
AU2002351909A1 (en) | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | |
EP2269988B1 (en) | Anthranilic acid amides and pharmaceutical use thereof | |
EP1572686B1 (en) | Anthranilic acid amide derivatives and their pharmaceutical use | |
ES2359395T3 (es) | Amidas de acido antranílico y su uso farmacéutico. | |
JP2021512861A (ja) | 抗癌性化合物 | |
NZ543915A (en) | Anthranilic acid amides for use in retinopathy or neoplastic disease, and their process of preparation | |
ZA200402623B (en) | Anthranillic acid amides and pharmaceutical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20101105 Year of fee payment: 9 |
|
OBST | Application withdrawn |